In brief: Psivida, Eqitx, Ellex, BRC, AFT

Following its recent Nasdaq listing, Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has appointed the president and CEO of New Jersey-based Chugai Pharma USA, David J Mazzo, as a non-executive director.

Eqitx (ASX:EQX) has lost two of its Perth-based directors, Brian Nathanson and Geoff Harland, following the company's relocation to Melbourne earlier this year.

David Lindh has retired as Ellex Medical's (ASX:ELX) chairman to focus on his role as chairman of Adelaide-based Rundle Capital Partners. He is replaced by Victor Previn. Alex Sundich, CFO of Record Investments (ASX:RCD), has been appointed to the board.

The Brain Resource Company (ASX:BRC) has raised AUD$1.6 million in a private placement of 5.9 million ordinary shares representing 7.5 per cent of the company's existing share capital. It has also appointed Bivest Group CEO Brian Joffe as a non-executive director. A private entity associated with Joffe subscribed to around half of the placement.

AFT Corp (ASX:AFT) has completed the acquisition of Microgenix System and now owns 100 per cent of its air purification technology. Philip Hall has resigned as a director of AFT and Microgenix, although he will remain as a consultant to AFT. The company has issued just over 44 million shares and 2 million convertible notes at a face value of $1 each to TechSuccess, a company associated with Hall.